Consent Forms Resource

Check out this great resource for Consent Forms from PPIB Insurance Services
http://www.ppibcorp.com/client-forms.html

Botox jab could ease arthritis and cancer without side effects

Botox jab could ease arthritis and cancer without side effects: Single injection could offer pain relief for months

• New molecule created by Sheffield University's Professor Bazbek Davletov 
• Could provide pain-numbing effect of Botox without freezing the muscles
• Created by fusing elements of Botox with those from the tetanus bug

By FIONA MACRAE, SCIENCE CORRESPONDENT

PUBLISHED: 19:57 EST, 29 October 2013 | UPDATED: 22:33 EST, 29 October 2013

A new drug created from Botox by a Sheffield University researcher could provide months of pain relief (file photo)

Botox, best known for smoothing out wrinkles, could also help soothe the pain of cancer, arthritis and migraines – without any side effects. 

Sufferers of chronic back pain and women who have given birth by Caesarean section could also benefit from the ‘super-Botox’ jab.

A single injection could provide pain relief for months – removing the need for patients to take several daily doses of powerful tablets – and it could be injected into any part of the body. 

Charities said the drug, invented by a researcher at Sheffield University, could revolutionise the treatment of pain.

The main ingredient of the Botox used to prevent wrinkles is a bacterial poison known as botulinum.

It works by preventing nerve cells from talking to muscles, which in turn stops muscles moving and wrinkles developing.

It can also stop pain signals from being transmitted for months at a time. 

However, fears that it will paralyse the area being treated have prevented it from being widely used for pain relief.

To get round this, Sheffield University researcher Professor Bazbek Davletov took the pain-relieving part of Botox and ‘stapled’ it to a friendly part of a similar poison produced by the tetanus bug.

The tetanus toxin ferries the pain-reliever to the spinal cord, where it stops pain signals being sent to the brain.

The professor said: ‘In effect, we engineer pain relief by taking only good parts of toxic molecules.’ 

Animal trials have had encouraging results and, if large-scale trials on people are successful, the drug could be on the market in as little as three years.

Professor Davletov designed the drug while working at the MRC Laboratory of Molecular Biology in Cambridge.

Painkiller: The new 'super-Botox' drug could help treat sufferers of chronic pain (file photo)

He said: ‘Currently painkillers relieve lingering pain only temporarily and often have unwanted side-effects. An injection of this new molecule at the site of pain could potentially relieve pain for many months.’ 

And he added that a public which is willing to have injections for cosmetic purposes would not be squeamish about receiving medicine in the same way. 

Migraine sufferers are likely to be the first to benefit. 

Normal Botox can already be used as a treatment for crippling headaches, but fears that it will paralyse the face mean that many sufferers miss out. 

'An injection of this new molecule at the site of pain could potentially relieve pain for many months'
- Professor Bazbek Davletov, Sheffield University

Cancer patients would also be high on the list as the side-effects of powerful painkillers such as morphine can be unbearable.

Drugs widely used to ease the pain of arthritis can raise the risk of heart attacks and around one in five people who have a major operation are left in pain for several years.

Professor Davletov, who reports his research in the journal Bioconjugate Chemistry, hopes the drug will cost around £1,000 a year, making it cheap enough for use on the NHS.

Martin Ledwick, of Cancer Research UK, said: ‘Alongside developing new treatments for cancer, finding new and better ways of controlling pain is very important. 

‘If this new approach proves to be effective and have fewer side effects, it has the potential to be extremely useful to cancer patients and others with chronic pain.’ 

Dr Fayyaz Ahmed, a neurologist, is a trustee for charity The Migraine Trust and chairman of the British Association for the Study of Headache.

He said: ‘This sounds interesting and innovative, and if successful in what it is meant to achieve may revolutionise the way we currently treat pain and other neurological disorders.’ 

Many A-list celebrities, including Nicole Kidman, Jennifer Aniston, Cindy Crawford and Dannii Minogue, have admitted having Botox in the past.

Read more: http://www.dailymail.co.uk/news/article-2479300/Botox-jab-ease-arthritis-cancer-effects.html#ixzz2jnaaGXc1

Allergan Licenses Rights To Medytox Candidates, In Up-To-$362M Deal

In a deal that could net Medytox up to $362 million, the Seoul-based company will license to Allergan exclusive global rights outside Korea to develop and commercialize unspecified neurotoxin product candidates now in development phases, including a potential liquid-injectable product, the companies said today.

In return for the license, Allergan will pay Medytox $65 million up front, up to $116.6 million in potential payments tied to undisclosed development milestones, and another up to $180.5 million in potential payments tied to undisclosed commercialization milestones, plus royalties on product sales.

According to its website, Medytox plans to grow into the global leader in the botulinum toxin pharmaceutical market by entering North America and the European Union markets during 2014.

Under the names Neuronox® and Siax®, Medytox markets botulinum toxin, a neurotoxin produced by Clostridium botulinum, with cosmetic uses in reduction of facial wrinkles as well as medical indications for relaxation of muscle spasms caused by blepharospasm,cerebral palsy and other disorders. Neuronox is sold in about 40 countries to users seeking either therapeutic or aesthetic treatments.

Allergan markets the prescription drug Botox® (onabotulinumtoxinA), now approved in some 85 countries for 25 different indications to help patients worldwide suffering from serious or debilitating conditions. In the United States, approved therapeutic indications include blepharospasm, cervical dystonia, chronic migraine, severe primary axillary hyperhidrosis, strabismus, upper limb spacticity, and urinary incontinence.

A related prescription product, Botox Cosmetic, is approved for injection into muscles to temporarily improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults younger than 65 years of age. Earlier this month, Allergan won FDA approval to market Botox Cosmetic for an additional indication to temporarily treat moderate to severe lateral canthal or "crow's feet" lines.

Botox is among pharmaceuticals, biologics, medical devices, and over-the-counter consumer products marketed by Allergan, whose specialties include eye care, neurosciences, medical aesthetics, medical dermatology, breast aesthetics, obesityintervention, and urologics.

original article can be loaded here 

http://www.news-medical.net/news/20130926/Allergan-Licenses-Rights-To-Medytox-Candidates-In-Up-To-24362M-Deal.aspx

Botulinum Toxin Type A New Information About an Old Medicine

Abstract

Now that several formulations of botulinum toxin type-A (BoNT-A) are on the market in North America and throughout the world, it is of great practical importance for those who administer these medications to be familiar with the differences between the formulations. These differences pertain to the stability of the medications, in particular during the period of time between reconstitution and administration, which may affect the degree of diffusion through various tissues after injection. A variety of relatively new uses of BoNT-A for dermatological conditions will be discussed.

Introduction

Medicines formulated from the highly purified, naturally occurring protein known as botulinum toxin type-A (BoNT-A) have been in use since 1980, when ophthalmologist Alan Scott used an injectable formulation of BoNT-A to treat strabismus and blepharospasm in humans. The first formulation of BoNT-A to become commercially available was onabotulinumtoxinA (BOTOX®), licensed in the United States in 1989 for treatment of three conditions: strabismus, blepharospasm, and hemifacial spasm. In recent years, two other formulations of BoNT-A have been licensed for use in the United States and a number of other countries: abobotulinumtoxinA (Dysport®) and incobotulinumtoxinA (XEOMIN®).

Those interested in BoNT-A should become familiar with the non-proprietary names for the various formulations of BoNT-A, because increasingly, presentations at meetings and in scientific publications are using the non-proprietary rather than the trade names for these products.^[1] A different non-proprietary name was assigned to each formulation of BoNT-A to reflect the fact that while the active ingredient in all three formulations is BoNT-A, the biological activity, in particular the stability and diffusion kinetics,^[2,3] of the active ingredient is modulated by the other components of the formulation, notably the protective proteins (hemagglutinins and non-hemagglutinins, which are associated with BoNT-A in onabotulinumtoxinA and abobotulinumtoxinA) and the amount and type of human serum albumin (added to the formulations to keep the BoNT-A in solution after reconstitution). Biological activity is also affected by the manufacturing process (as each BoNT-A formulation is manufactured differently), as well as other excipients in the vial (e.g., sodium chloride and sucrose). The effects (if any) on stability after reconstitution caused by the presence of trypsin-like proteolytic activity in incobotulinumtoxinA^[4] remain to be elucidated.

Continue Here ...

Kevin C. Smith, MD, FRCPC (Dermatology)

Skin Therapy Letter. 2011;16(8) 

Platelet-Rich Plasma Procedure May Improve Facial Appearance

Laurie Barclay, MD, Alan Matarasso, MD, Lauren Zeifman, rPA-C

Editor's Note:

Platelet-rich plasma (PRP) therapy involves injection of the patient's own platelets and fibrin for the cosmetic treatment of wrinkles or scars in the face, hands, and neck. Known to some as the "vampire facelift" (a term trademarked by Alabama cosmetic surgeon Charles Runels), it is less invasive than plastic surgery, takes about 20 minutes for each treatment, and offers improvements for up to 18 months. Cost of the procedure is generally similar to that of fillers and may range from $600 to $1800 per treatment.

However, the efficacy and safety of PRP for cosmetic treatment have not been studied in controlled clinical trials. To learn more about the role of PRP therapy in cosmesis, Medscape interviewed Alan Matarasso, MD, and Lauren Zeifman, rPA-C, both in clinical practice in New York City.

Dr. Matarasso is Clinical Professor of Plastic Surgery at Albert Einstein College of Medicine and has hospital privileges at numerous New York City medical institutions, including Manhattan Eye, Ear & Throat Hospital and New York Eye & Ear Infirmary. His contributions to many areas of aesthetic surgery include pioneering advances in surgical and noninvasive techniques. He is widely published and is the senior scientific editor of the Aesthetic Surgery Journal.

Medscape: Please define the PRP therapy procedure for improving facial appearance.

Dr. Matarasso and Ms. Zeifman: Selphyl® (UBS Aesthetics; Bethlehem, Pennsylvania) is a patented system for safe and rapid preparation of platelet-rich fibrin matrix, which is a type of regenerative medicine that uses platelets to rejuvenate the skin.

Medscape: What is the rationale behind the use of PRP therapy to improve facial appearance?

Dr. Matarasso and Ms. Zeifman: A steady trend over the past 15 years has been for patients to seek less-invasive procedures for facial rejuvenation. Selphyl has been used by surgeons over the past 7 years to speed up soft-tissue healing from sports injuries as well as to treat burn victims and patients with severe ulcers. It is also used as an adjunct to implant therapy in dentistry.

Selphyl is now being used cosmetically to treat volume loss in the face, hands, and neck -- particularly the crepey skin under the eyes and neck -- as well as wrinkles, acne scarring, and stretch marks.

Medscape: By what mechanisms do injections of PRP restore facial appearance?

Dr. Matarasso and Ms. Zeifman: Platelets play a role in stopping bleeding and in repairing damaged blood vessels and cells in the body. Platelets also contain substances called "growth factors" that activate and rejuvenate cells in our body. Unlike fillers that use various synthetic substances, Selphyl uses the patient's natural biology to address skin defects and volume loss, triggering production of new cells and collagen formation.

Medscape: How long does the procedure take, and how is it performed?

Dr. Matarasso and Ms. Zeifman: This cutting-edge rejuvenation is a quick 20-minute procedure. After 9 cm³ of blood (approximately 1 vial) is drawn from the patient, it is spun down in a centrifuge for 6 minutes at a precalculated speed to retrieve the most viable fibrin and platelets. After centrifugation, the platelet and fibrin component of the blood (the top layer) is extracted and reinjected into the area of concern.

Medscape: What type of results can generally be expected?

Dr. Matarasso and Ms. Zeifman: The results are subtle, with gradual improvement in the injected area over a 3- to 5-week period. Full correction occurs at 4-7 weeks and can last as long as 18 months.

Medscape: What are the risks or complications?

Dr. Matarasso and Ms. Zeifman: Because this filler is made from the patient's own blood, there is no risk for rejection, infection, or an allergic reaction.

Medscape: For what types of patients is this procedure most and least suitable?

Dr. Matarasso and Ms. Zeifman: Any patient who wishes to reduce volume loss, fine lines, and textural changes of the skin is suitable for this procedure. It also appeals to the patient who is looking for a natural approach to volumizing the face and treating or reducing fine lines.

Medscape: How long are the improvements maintained? If necessary, can the procedure be repeated, and if so, with what anticipated outcome?

Dr. Matarasso and Ms. Zeifman: Selphyl can be repeated, and better results are seen with a total of 2-3 treatments given 3-4 months apart. Patients can expect to see better results as they receive more treatments. With time, the results of Selphyl get better and better.

Medscape: How does PRP therapy compare with injections of filler, Botox(Botox® Cosmetic; Allergan, Inc; Irvine, California), or surgical facelifts?

Dr. Matarasso and Ms. Zeifman: This procedure can be combined with dermal fillers, Botox injections, and laser surgery, as well as facial surgery. PRP builds tissue over time, whereas traditional filler breaks down over time.

Medscape: In what situations might PRP therapy plus filler injections be helpful?

Dr. Matarasso and Ms. Zeifman: It is nice to layer Selphyl with traditional fillers. If a patient has volume loss with a lot of fine lines and textural changes, I like to inject Selphyl to create a new foundation of collagen and use dermal fillers for the fine lines.

Medscape: What is your overall opinion of the role that PRP therapy should play in facial restoration?

Dr. Matarasso and Ms. Zeifman: PRP therapy is very promising in facial restoration. Results are optimal when patients receive a combination of PRP, dermal fillers, and laser therapy.

Platelet-Rich Plasma Procedure May Improve Facial Appearance. Medscape. Mar 06, 2012.

AAMEP Announces Fall, Miami Beach Conference Schedule October 5-6

AMERICAN ACADEMY OF MEDICAL ESTHETIC PROFESSIONALS - AAMEP

AAMEP Members and Guests,

On behalf of the officers at AAMEP we would like to thank you for your support. We have prepared a very exciting program; with interesting presentations and live demonstrations.   We are confident you will find the information educational, stimulating, and FUN!

We are proud to offer 9.5 CE’s and CME’s for attending the 7th Annual AAMEP conference.  We wish you great success in your medical esthetic practices.

On a side note:

We are looking to fill the position for the State Chairman for your state.

In light of what is going on all over the country with the Dermatology community trying to inhibit and prohibit our practice of esthetics by their attempts to introduce legislation (to limit and restrict) we need now more than ever to have active participants and responsible communicators.

We are asking for your commitment to your organization to assist and work with your fellow members to strengthen and nurture our organization for the good of all members.

This will not take up much of your time; only a few hours per month to keep abreast of any new bills that may have been introduced to your House of Representatives and State Senate.  You will have direct communication with your Regional Director and President of AAMEP. 

Opportunities for involvement are greatly welcomed.  Your energy and presence is needed in committees, Workgroups, and Task Forces.  The AAMEP board of Directors is here to serve you.  Our continued goal is to implement state and national coalitions to collectively address priority Association issues:  legislative changes, scope of practice, membership recruitment, malpractice insurance needs, and more.  Please let us know your interest.

Warm Regards,

Sasha Parker 

President

8th ANNUAL CONFERENCE

PROGRAM SCHEDULE

The Palms Hotel and Spa

3025 Collins Ave Miami Beach , FL 33140

PRE-CONFERENCE

Friday, October 4, 2013

“WELCOME SOCIAL”

7:30 PM – 10:30 PM   ALL MEMBERS, ATTENDEES, VENDORS WELCOME!  Location/Room: TBA

CONFERENCE DAY I

Saturday, October 5, 2013

 Location/Room -TBA (9am-6pm)

Breakfast  08:00 – 09:00am Location

Exhibits  8:00am – 5:30pm Location

              08:00 – 09:00   Registration; Breakfast with the Exhibitors (Sponsored by AAMEP)

09:00      WELCOME: AAMEP News, Legislative Updates, Market Trends; President Sasha Parker, RN, MEP-C

09:30      Leslie Blanche: Aesthetic Marketing and Trends

10:30      COFFEE AND DEMONSTRATIONS WITH THE EXIBITORS

11:15      TBA

12:15       Michelline Hajj, RN  -TBA

1:00        LUNCH (Sponsored by AAMEP)

2:30        Dr. Shino Bay Aguilera: Sculptra & Your Practice, With Live Demonstration  

3:30        Dr. Elliot Battle: Current Trends in Treating Skin of Color

4:30        Coffee Break and Vendors

5:00        DAY 1 ENDS

             

AMERICAN ACADEMY OF MEDICAL ESTHETIC PROFESSIONALS

AAMEP

CONFERENCE - DAY II

Sunday, October 23, 2011

Location/Room: TBA (9:00am -4:15pm)

Breakfast  9:00-10:00am   Location TBA

Exhibits open 8:30am – 5:00pm

09:00      REGISTRATION & BREAKFAST WITH THE EXIBITORS (Sponsored by AAMEP)

10:00      Cheryl Whitman: Develop Your Customer Service Skills; Learn How to Deal With the 6 Different Types of Clients

11:00      Janelle Vega, MD: Sublative Rejuvenation- New Advances in Fractionated BiPolar RF

12:00      LUNCH ON YOUR OWN AND TIME WITH EXIBITORS

1:30        Stephen Holt, MD Integrative Medicine

2:30        Tanya Bower, ESQ Protecting Your Assets in a High Risk World

3:30        Coffee Break and Exhibitors   

4:00        Sasha Parker, MEP-C The Many Amazing Uses of Platelet Rich Plasma and conference wrap up!

CONFERENCE ENDS

FEATURED SPEAKERS

SASHA PARKER RN, MEP-C, President AAMEP- Board Chairman, Founding Member; Sasha Parker is the President and Founder of Esthetic Skin Institute, Inc and was the original innovator and 1st trainer of “medical esthetic hands-on” workshops” and has personally trained thousands of medical professionals internationally for over 13 years. She has trained with many medical esthetic experts throughout the world, and has a passion for sharing that knowledge with colleagues.

Sasha Parker: The Many Amazing Uses of PRP -Platelet Rich Plasma has been used in Europe with great success in clinical practice since the late 1980’s. Initially used to enhance wound healing in many specialties, it’s emergence into the aesthetic/cosmetic arena for rejuvenation of skin started in 2004. The Skin rejuvenation technique has been used since 2004 in Europe, Asia, and South America. Patients have seen all around improvement in skin texture, pigmentation disorders, fine lines and wrinkles, scars, acne, stretch marks, and hair loss to name a few. Studies show that PRP, when done properly, has the ability to increase collagen deposition and remodeling which can persist over a 12 month period. The term autologous means that the source of origin is the patient’s own body and because of this is desirable to many patients who may desire a natural type treatment.

ELIOT F. BATTLE, JR, MD;  Dr Battle is considered one of the world’s best cosmetic dermatologists and laser surgeons and recognized as the leading authority of cosmetic laser therapy on people of color. His 3 year pioneering research at Harvard helped to invent the new generation of non-invasive “color blind” cosmetic lasers opening up the field to patients of all cultures, regardless of skin of color or ethnicity.  

Eliot Battle, MD will be discussing the current trends in treating skin of color. This discussion has been developed in response to the ever-increasing demand for dermatologic treatments in patients with skin of color, and the accompanying need for education and training in this quickly expanding market. 

Cheryl Whitman, CEO beautiful forever Aesthetic Business Consulting Cheryl Whitman is an internationally recognized pioneer in medical spa and aesthetic medical business consulting.  Cheryl is a published author, popular speaker and cosmetic marketing specialist.  As founder and CEO of beautiful forever, Cheryl spearheads a successful team of aesthetic business consultants and business professionals.

Cheryl’s diverse background enables her to provide her clients with the highest level of personal attention, along with top-notch consulting support. Frequently quoted by news media such as the New York Times and a host of industry trade journals, she has worked with clients helping them to improve their business practices and their bottom lines.

Cheryl Whitman Develop Your Customer Service Skills- Learn how to successfully deal with the 6 different types of clients. Cheryl will discuss learning how to properly and effectively manage your relationships with the new patient, the undecided patient, the difficult patient, the negotiating patient, the shopper, and the VIP.   

Shino Bay Aguilera, MD Dr. Shino Bay Aguilera is a world renowned Cosmetic Dermatologist, Dermatologic Surgeon, Cosmetic Laser Expert, and is Dual Board certified with a Fellowship in Dermatology from the American College of Osteopathic Dermatology. He has over 16 years of ongoing advanced training in lasers and Aesthetics and is a clinical researcher, publisher, and Medical Director of NOVA University Dermatology residency program and Assistant Professor of Dermatology for four other Universities. A top-requested International physician trainer and keynote speaker, Dr. Aguilera travels the world teaching physicians the proper use of the newest laser advances and cosmetic techniques.

Dr. Shino Bay Aguilera Will be discussing treatment protocols for the most optimal use of Sculptra Aesthetic for enhancement and volumization.  Dr Aguilera is the Number one Sculptra user in the United States and is a world speaker on this topic. He will also do a live demo.   

Tanya Bower, ESQ a director with Tripp Scott Firm, focuses her practice on corporate and tax matters, including estate planning, asset protection and wealth preservation. She counsels owners of closely-held businesses on estate-planning matters and help clients in a wide range of businesses on ERISA matters, including establishing, amending and terminating pension plans.  In addition, she is experienced at drafting corporate contracts and other documents; establishing and dissolving corporations, limited-liability companies and partnerships; and representing owners in acquisitions and mergers, including analyzing the tax aspects of these transactions.

Tanya Bower, ESQ, PA will be discussing Asset Protection “Now that you’ve made it, don’t lose it!”  Tonya will address important topics such as tax liabilities, separating your assets, assets exempt from creditors, assets owned by entities, estate planning and more. With a question and answer period for attendees. Now is your chance for free legal advice.

Janelle Vega, MD is a board certified dermatologist and received her undergraduate degree from Haverford College in 2002, followed by an M.D. degree in Gainesville, FL from the University of Florida College of Medicine in 2006. She completed a post-doctoral training in Internal Medicine at Beth Israel Deaconess Medical Center in Boston, a Harvard medical school affiliate. She also did a year of clinical research at the University of Puerto Rico where she also fulfilled her first year of dermatology training. She concluded her dermatologic training at the University of Miami Miller School of Medicine, where she received an award for Excellence in Dermatologic Surgery. She is the author of several medical articles, and book chapters.

Janelle Vega, MD is speaking about  Skin Rejuvenation with Sublative fractionated bi-polar radio frequency technology which places the heat energy effectively into the upper dermis where it can produce a significant increase in both collagen and elastin with minimal epidermal disruption.

Leslie Blanche As a senior healthcare marketing manager with HRB, Leslie brings experience working in the medical marketing field. Leslie specializes in working closely with hospitals, device companies and physician practices to hone and develop their personal philosophy into a distinct and identifiable message that will help them earn the trust of their communities and industries and, ultimately, to help them grow. She has implemented successful marketing campaigns for physicians and hospitals across the US and Canada.

Stephen Holt, MD Integrative Medicine is a best-selling author and medical practitioner in New York. He has been described as a visionary, a pioneer of Integrative Medicine and is world-renowned for his work on nutrition and dietary supplements. He is a frequent guest lecturer at medical and scientific conferences.

For many years, Dr. Holt has developed management pathways for several public health initiatives, with an emphasis on lifestyle changes and nutritional interventions. He believes that healthcare should be portable, widely available and free for children and the elderly. Dr. Holt has been described as the “doctor’s doctor” because many of his patients are medical practitioners. Because of the major pressure on Dr. Holt’s time as an international lecturer etc., he restricts his patient care to referrals only from other doctors.

Dr. Holt’s principal training has been in allopathic medicine, but he has charted new treatment paradigms using natural medicines. He believes in the concept of “medical pluralism”, where many different medical disciplines come together to provide holistic healthcare. Dr. Holt supports the practice of many forms of medicine including: chiropractic medicine, naturopathic medicine, podiatric medicine, homeopathic medicine, as well as traditional medical disciplines that offer many alternative strategies for health maintenance.

He is an author of more than 20 books in the popular healthcare field and he has also contributed chapters and many articles to peer-reviewed medical textbooks and journals. As well as publishing several hundred scientific articles in leading medical journals, Dr. Holt has been cited thousands of times in the medical and lay press.

An honors graduate in medicine from Liverpool University Medical School, in England, UK, Dr. Holt holds sub-specialty qualifications in gastroenterology and internal medicine in the USA, Canada and Europe. He has practiced clinical medicine for four decades. Dr. Holt has held the rank of full professor of medicine and bioengineering (adjunct) for many years and he has received awards for medical teaching and research, in the United States, China, Indonesia, Great Britain, Malaysia, Thailand, Taiwan, South Korea and other countries, where he has served as a Visiting Professor. He now holds the highest academic rank as a Distinguished Professor of Medicine (Emeritus).

Dr. Holt was the recipient of an honorary appointment as a Professor of medicine at San Yat-sen University of Medical Sciences in China, an honor bestowed on only a small number of Western physicians. In 2005, Dr. Holt was honored with the degree of Doctor of Humane Letters for his contributions to education in medicine. He has been knighted by the Holy Order of St. John and serves as their Lieutenant Grand Hospitaller.

More to come 

to Join this event at a special price of 225.00 please click here 

FDA Advisory Committee Unanimously Recommends JUVÉDERM VOLUMA™ XC as a Safe and Effective Treatment Option for Cheek Augmentation to Correct Age-Related Volume Deficit in the Mid-Face

IRVINE, Calif.--(BUSINESS WIRE)-- Allergan, Inc., (NYSE: AGN) is pleased that the U.S. Food and Drug Administration (FDA) General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee has voted unanimously that the benefits of JUVÉDERM VOLUMA™ XC, an injectable hyaluronic acid dermal filler for cheek augmentation to correct age-related volume deficit in the mid-face, outweigh the risks. If approved, JUVÉDERM VOLUMA™ XC would be the first and only dermal filler in the United Stateswith this indication.

"Today's recommendation is an important step in the FDA review process for JUVÉDERM VOLUMA™ XC," said Scott M. Whitcup M.D., Executive Vice President, Research and Development, Chief Scientific Officer, Allergan. "Allergan is committed to working with the FDA as they continue their review of our PMA for JUVÉDERM VOLUMA™ XC, with the goal of providing consumers with the first treatment option that has been specifically developed to help restore cheek volume that has been lost over time."

The Advisory Committee's recommendation, although not binding, will be considered by the FDA when making the final approval decision for JUVÉDERM VOLUMA™ XC. If approved by the FDA, Allergan anticipates launching JUVÉDERM VOLUMA™ XC in late 2013.

For Training www.esiw.com

To Read Full Article  http://agn.client.shareholder.com/releasedetail.cfm?ReleaseID=761662